Publications by authors named "S B Schalm"
Murine double minute 2 (MDM2) is an E3 ligase that inhibits the tumor suppressor protein p53. Clinical trials employing small-molecule MDM2/p53 interaction inhibitors (SMIs) have demonstrated limited activity, underscoring an unmet need for a better approach to target MDM2. KT 253 is a highly potent and selective heterobifunctional degrader that overcomes the MDM2 feedback loop seen with SMIs and induces apoptosis in a range of hematologic and solid tumor lines.
View Article and Find Full Text PDFArticle Synopsis
- Many non-small-cell lung cancer (NSCLC) patients develop resistance to existing EGFR tyrosine kinase inhibitors (TKIs), particularly due to _C797S mutations that render osimertinib ineffective.
- BLU-945 is a new orally available EGFR-TKI that effectively targets both activating and resistance mutations, including EGFR_C797S, showing significant potency while sparing healthy EGFR.
- In preclinical and early clinical studies, BLU-945 demonstrated promising results, inhibiting tumor growth in resistant models and patients, suggesting it could be a viable treatment option for NSCLC patients who no longer respond to osimertinib.
Background And Aims: Systematic reviews and medical guidelines are widely used in clinical practice. However, these are often not up-to-date and focussed on the average patient. We therefore aimed to evaluate a guideline add-on, TherapySelector (TS), which is based on monthly updated data of all available high-quality studies, classified in specific patient profiles.
View Article and Find Full Text PDFObjective: The aim of this study was to develop and psychometrically validate a self-report instrument to assess (1) competencies, (2) needs, and (3) satisfaction among youth transitioning from pediatric to adult rheumatology.
Methods: The Transition-KompAZ was developed in several steps with conceptual and psychometric analyses. To test its psychometric properties, the instrument was administered to adolescents and young adults (AYAs; 16-25 years) with inflammatory rheumatic diseases before (group 1) or after (group 2) transfer to adult rheumatology.